Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 4 clinical trials
Apixaban for Intrahepatic Non Cirrhotic Portal Hypertension

intrahepatic thromboses and consequently liver disease progression and variceal bleeding. The Primary Objective is to evaluate the effect of 24 months low dosing of apixaban (2.5 mg x 2/day) versus

  • 0 views
  • 04 Mar, 2021
  • 1 location
API-CAT STUDY for APIxaban Cancer Associated Thrombosis

The main objective is to determine whether a low-dose regimen of apixaban (2.5 mg bid) is non inferior to a full-dose regimen of apixaban (5 mg bid) for the prevention of recurrent venous

  • 8 views
  • 05 Mar, 2021
  • 120 locations
REduced Dose Versus Full-dose of Direct Oral Anticoagulant After uNprOvoked Venous thromboEmbolism.

Patients with unprovoked venous thromboembolism (VTE) or VTE associated with persistent risk factors have a high risk of recurrence after stopping anticoagulation. In these patients, international guidelines recommend indefinite anticoagulation. However, prolonged use of warfarin or DOAC at therapeutic dose is associated with a significant risk of bleeding. Consequently, it …

warfarin
rivaroxaban
apixaban 2.5 mg
apixaban
anticoagulation therapy
  • 7 views
  • 27 Jan, 2021
  • 59 locations
Efficacy and Safety of Apixaban in Reducing Restenosis and Limb Loss in PAD Patients.

This study will evaluate the efficacy and safety of apixaban 2.5 mg twice daily plus aspirin compared to the standard treatment (clopidogrel plus aspirin) in patients with critical limb ischemia

endovascular procedure
aspirin
serum pregnancy test
limb ischemia
clopidogrel 75 mg
  • 0 views
  • 26 Apr, 2021
  • 1 location